WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Iowa law allows police to arrest and deport migrants. Civil rights groups are suingAmnesty urges FIFA to release compensation review for Qatar World Cup migrant workersBoeing 737 catches fire and skids off the runway at a Senegal airport, injuring 10 peopleEurope Day: Celebrations stay humdrum as all eyes on crucial EU electionKing Charles was 'delighted' and 'playful' at garden party at Buckingham PalaceFresh health warning over ultraHuge fire at a chemical storage tank in Thailand kills one and injures 4Apple's new iPad advert featuring musical instruments being crushed is SLAMMED by criticsHarvey Weinstein won't be extradited to California while he awaits New York rape retrialProud Lionness! Mary Earps beams as she's honoured by William
2.8583s , 6501.6328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Pulse news portal